PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
9.68M
Better than VKTX's estimated revenue of 2.27M.
-1.93M
Worse than VKTX's estimated ebitda of 0.
-1.38
Better than VKTX's estimated eps of -1.48.
-41.62M
Better than VKTX's estimated net income of -167.24M.
-1.93M
Worse than VKTX's estimated ebit of 0.
358.54M
Worse than VKTX's estimated sg&a expense of 0.
Analyze DCF forecasts for the company and compare them with competitors.
No Data
No DCF data available for this metric in the selected year.
-50.53%
Worse than VKTX's revenue growth rate of 0.00%.
No Data
No DCF data available for this metric in the selected year.
-20.00%
Worse than VKTX's ebitda margin of 100.00%.
No Data
No DCF data available for this metric in the selected year.
-20.00%
Worse than VKTX's ebit margin of 100.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
100.00%
Equal to VKTX's cash as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
40.00%
Better than VKTX's receivables as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
40.00%
Better than VKTX's inventories as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Equal to VKTX's payables as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
-29.43%
Better than VKTX's capex as percentage of revenue of 0.00%.
4.99%
Better than VKTX's weighted average cost of capital (wacc) of 8.95%.
5.02%
Better than VKTX's cost of equity of 8.95%.
4.08%
Better than VKTX's cost of debt of 6.98%.
-0.23
Better than VKTX's beta of 0.99.
30.07M
Better than VKTX's diluted shares outstanding of 94.35M.
1.57M
Worse than VKTX's total debt of 1.26M.
49.31M
Worse than VKTX's total equity of 3.96B.
50.89M
Worse than VKTX's total capital of 3.96B.
3.09%
Worse than VKTX's debt weighting of 0.03%.
96.91%
Worse than VKTX's equity weighting of 99.97%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
2.00%
Equal to VKTX's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Better than VKTX's net debt of -54.26M.
71.33M
Better than VKTX's equity value of 47.36M.
2.37
Better than VKTX's equity value per share of 0.50.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.